Allergic Rhinitis Pipeline Review, H2 2019 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Allergic Rhinitis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 1, 6, 13, 8, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 4 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Allergic Rhinitis - Overview
3. Allergic Rhinitis - Therapeutics Development
4. Allergic Rhinitis - Therapeutics Assessment
5. Allergic Rhinitis - Companies Involved in Therapeutics Development
6. Allergic Rhinitis - Drug Profiles
7. Allergic Rhinitis - Dormant Projects
8. Allergic Rhinitis - Discontinued Products
9. Allergic Rhinitis - Product Development Milestones
10. Appendix

Companies Mentioned

• Advagene Biopharma Co Ltd
• ALK-Abello AS
• Allovate LLC
• AOBiome LLC
• ASIT Biotech SA
• Chrysalis BioTherapeutics Inc
• CSPC Pharmaceutical Group Ltd
• Dobecure SL
• Emergo Therapeutics Inc
• Fountain Biopharma Inc
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd
• HAL Allergy BV
• Inimmune Corp
• Inmunotek SL
• JiangSu Qyuns Therapeutics Co Ltd
• Kolmar Korea Holdings Co Ltd
• Laboratorios LETI SL
• Link Health Group
• Marinomed Biotech AG
• Mitsubishi Tanabe Pharma Corp
• Navipharm Co Ltd
• Paradigm Biopharmaceuticals Ltd
• Pfizer Inc
• Regeneron Pharmaceuticals Inc
• Roxall Medizin GmbH
• Sam-A Pharm Co Ltd
• Sedor Pharmaceuticals LLC
• Shouyao Holding Co Ltd
• Stallergenes Greer plc
• The Geneva Biotech Center SA
• Vactech Oy
• Wolwo Pharma
• Wuhan Yicheng Biotechnology Co Ltd
• Xencor Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lujn0y